Advertisement
News
Subscribe to MDT Magazine News

Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.

March 2, 2011 4:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 2, 2011 /- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an...

TOPICS:

Myriad board approves $100 million buyback plan

March 2, 2011 3:45 am | by The Associated Press | Comments

Myriad Genetics Inc. said Wednesday its board of directors approved a $100 million stock buyback program.The company said it will repurchase $50 million in stock from J.P. Morgan as part of the new program.The remaining $50 million will be repurchased through open market or privately negotiated...

Nile Therapeutics Receives Positive NASDAQ Panel Decision

March 2, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN MATEO, Calif., March 2, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on March 1, 2011, the Company received a positive determination from the NASDAQ Listing Qualifications...

TOPICS:
Advertisement

Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairs's VistA Imaging System

March 2, 2011 3:34 am | by Bio-Medicine.Org | Comments

MELBOURNE, Fla. and WASHINGTON, March 2, 2011 /- Highlights: System serves more than 1.3 million patients and captures more than 35 million images each month Critical component of VA's mission to provide multimedia patient health records at point of care One of the most comprehensive and...

TOPICS:

Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance

March 2, 2011 1:36 am | by Bio-Medicine.Org | Comments

HOUSTON, March 2, 2011 /- Cyberonics, Inc. (Nasdaq: CYBX ), a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.   Quarterly HighlightsOperating results and achievements for the third quarter of fiscal 2011 compared to the third...

TOPICS:

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting

March 2, 2011 1:34 am | by Bio-Medicine.Org | Comments

BOULDER, Colo., March 2, 2011 /- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule...

TOPICS:

Effectiveness of wastewater treatment may be damaged during a severe flu pandemic

March 1, 2011 8:40 pm | by EurekAlert | Comments

(Centre for Ecology & Hydrology) Existing plans for antiviral and antibiotic use during a severe influenza pandemic could reduce wastewater treatment efficiency prior to discharge into receiving rivers, resulting in water quality deterioration at drinking water abstraction points,...

TOPICS:

Study shows pine bark naturally improves kidney function in patients with metabolic syndrome

March 1, 2011 8:35 pm | by EurekAlert | Comments

(MWW Group) A study published in the June 2010 issue of Panminerva Medica reveals Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, demonstrates kidney health benefits in metabolic syndrome patients, with effective blood pressure...

TOPICS:
Advertisement

Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk

March 1, 2011 5:35 pm | by Bio-Medicine.Org | Comments

RICHMOND, Va., March 1, 2011 /- Health Diagnostic Laboratory Inc. (HDL, Inc.), www.myhdl.com , announced today its partnership to develop a novel laboratory developed test with Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing diagnostic test and surgical therapy...

TOPICS:

STAAR Surgical reports narrower 4Q loss(2)

March 1, 2011 3:46 pm | by The Associated Press | Comments

Implantable eye lens maker STAAR Surgical Co. reported a narrower fourth-quarter loss Tuesday on higher sales.STAAR said it lost $691,000, or 2 cents per share, in the final quarter of 2010. For the year earlier, it reported a loss of $1.5 million, or 4 cents per share. Revenue rose 8 percent...

STAAR Surgical reports narrower 4Q loss

March 1, 2011 3:45 pm | Comments

Implantable eye lens maker STAAR Surgical Co. reported a narrower fourth-quarter loss Tuesday on higher sales.STAAR said it lost $691,000, or 2 cents per share, in the final quarter of 2010. For the year earlier, it reported a loss of $1.5 million, or 4 cents per share. Revenue rose 8 percent...

Acquisition costs hit Universal Health 4Q profit

March 1, 2011 1:45 pm | by The Associated Press | Comments

Hospital operator Universal Health Services Inc. said its profit decreased 39 percent in the fourth quarter on costs related to its acquisition of competitor Psychiatric Solutions, but the company's shares rose in Tuesday trading.Universal Health Services said its profit fell to $37.2 million,...

New report says large proportion of colorectal cancer deaths could be prevented

March 1, 2011 1:36 pm | by EurekAlert | Comments

(American Cancer Society) A new report from the American Cancer Society says a large proportion of the 141,000 cases and 49,000 deaths from colorectal cancer expected in the United States this year could be prevented by increasing the use of established screening tests and by...

TOPICS:

Dendreon posts bigger 4Q loss, Provenge sales grow

March 1, 2011 11:45 am | by The Associated Press | Comments

Dendreon Corp. said Tuesday that sales of its prostate cancer therapy Provenge rose to $25 million in the fourth quarter, but the company reported a larger quarterly loss as it ramped up its manufacturing capacity.Dendreon reported a loss of $91.8 million, or 64 cents per share, in the fourth...

Colliers reports slight drop in life sciences vacancy rate

March 1, 2011 10:39 am | by Mass High Tech: The Journal of New England Technology | Comments

Real estate firm Colliers International has released its semi-annual review of the Greater Boston life sciences sector and real estate trends in that market, noting that there are about 500 biotech companies in Massachusetts and 40 local colleges and universities offering advanced degrees...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading